Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy
Resource
Int. J. Cancer, 132(9), 1977-1985
Journal
International Journal of Cancer
Pages
1977-1985
Date Issued
2013
Date
2013
Author(s)
Chang C.H.
Hsiao C.F.
Yeh Y.M.
Chang G.C.
Tsai Y.H.
Chen Y.M.
Huang M.S.
Chen H.L.
Li Y.J.
Chen C.J.
Hsiung C.A.
Su W.C.
Abstract
Lung cancer is the leading cause of cancer death worldwide as well as in Taiwan. Interleukin-6 (IL-6) is a multifunctional cytokine and has been implicated in tumor progression. This study recruited 245 patients with advanced (Stage 3B/4) nonsmall cell lung cancer (NSCLC) that had received chemotherapy, to evaluate associations between IL-6 and lung cancer-specific survival. Among these subjects, 112 gave blood samples before and 133 after the start of chemotherapy. Plasma IL-6 was measured using an enzyme linked-immunosorbent assay. The 33rd and 66th percentiles of IL-6 concentrations were 2.01 and 25.16 for the 245 patients and were defined as the cutoff points for dividing the patients into low, intermediate and high groups. Kaplan-Meier and Cox proportional-hazard models were used to evaluate the relationship between the IL-6 level and survival time. Results after adjusting for age, sex, smoking history, histologic type and stage of lung cancer revealed a significant relationship. For all patients, the hazard ratio with high IL-6 levels for lung cancer-specific survival was 2.10 [95% confidence interval (CI) = 1.49 2.96] compared with low IL-6 levels. The hazard ratio for patients who were recruited before and after the start of chemotherapy was1.25 (95% CI = 0.73 2.13) and 3.66 (95% CI = 2.18 6.15), respectively. Patients with high circulating IL-6 also responded poorly to chemotherapy. Therefore, a high level of circulating IL-6 was associated with an inferior response and survival outcome in NSCLC patients treated with chemotherapy.
Subjects
lung cancer
survival
Interleukin-6
prognostic factor
SDGs
Other Subjects
antineoplastic agent; interleukin 6; age distribution; anamnesis; article; blood sampling; cancer chemotherapy; cancer prognosis; cancer specific survival; cancer staging; cancer survival; enzyme linked immunosorbent assay; gender; histopathology; human; Kaplan Meier method; lung non small cell cancer; major clinical study; priority journal; protein blood level; protein determination; protein expression; smoking; survival time; treatment outcome; Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Tumor Markers, Biological
File(s)![Thumbnail Image]()
Loading...
Name
index.html
Size
23.15 KB
Format
HTML
Checksum
(MD5):25f19f1d4ed24751484b8d9cae4c8a52